SUPN · Supernus Pharmaceuticals, Inc. · Documents
$41.52
+0.29 (+0.70%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$2.40B
Shares
58.13M
Volume · Oct 21
214.51K
Avg daily vol (3M)
808.16K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Supernus Pharmaceuticals will report third quarter 2026 financial and business results after market close on Thursday, October 29, 2026, followed by a conference call and webcast at 4:30 p.m. ET. | 2026-10-19 | — | |
| 8-K | On October 15, 2026, Supernus Pharmaceuticals, Inc. shareholders approved the merger agreement with Indivior Pharmaceuticals Inc. and non-binding compensation for named executive officers; Supernus will survive as a wholly owned subsidiary of Indivior. | 2026-10-15 | — | |
| DEFA14A | — | 2026-10-06 | — | |
| DEFM14A | — | 2026-09-11 | — | |
| DEFA14A | — | 2026-08-03 | — | |
| Investor Event Transcript | — | 2026-08-03 | 2026-09-30 | |
| 8-K | — | 2026-08-03 | — | |
| 8-K | — | 2026-08-03 | — | |
| DEFA14A | — | 2026-08-03 | — | |
| 10-Q | — | 2026-08-03 | 2026-06-30 | |
| 8-K | — | 2026-08-03 | — | |
| 8-K | — | 2026-08-03 | 2026-08-01 | |
| DEFA14A | — | 2026-08-03 | — | |
| 8-K | — | 2026-07-22 | — | |
| 8-K | — | 2026-06-18 | — | |
| Investor Event Transcript | — | 2026-06-03 | 2026-06-30 | |
| 8-K | — | 2026-05-20 | 2026-05-17 | |
| Investor Event Transcript | — | 2026-05-12 | 2026-06-30 | |
| 8-K | — | 2026-05-05 | — | |
| 10-Q | — | 2026-05-05 | 2026-03-31 | |
| ARS | — | 2026-04-30 | 2025-12-31 | |
| DEF 14A | — | 2026-04-30 | 2026-06-18 | |
| DEFA14A | — | 2026-04-30 | — | |
| 8-K | — | 2026-04-22 | — | |
| 8-K | — | 2026-04-07 | 2026-04-01 | |
| Investor Event Transcript | — | 2026-03-31 | — | |
| 10-K | — | 2026-03-02 | 2025-12-31 | |
| 8-K | — | 2026-02-24 | — | |
| 8-K | — | 2026-02-24 | — | |
| 8-K | — | 2026-02-12 | — | |
| 8-K | — | 2026-01-28 | — | |
| 10-Q | — | 2025-11-06 | 2025-09-30 | |
| 8-K | — | 2025-11-04 | — | |
| 8-K | — | 2025-10-21 | — | |
| 8-K/A | — | 2025-10-16 | 2025-07-31 | |
| 8-K | — | 2025-08-05 | — | |
| 10-Q | — | 2025-08-05 | 2025-06-30 | |
| 8-K | — | 2025-08-04 | 2025-06-16 | |
| SC TO-T/A | — | 2025-07-31 | — | |
| 8-K | — | 2025-07-31 | 2025-07-30 | |
| SC TO-T/A | — | 2025-07-28 | — | |
| 8-K | — | 2025-07-22 | — | |
| SC TO-T | — | 2025-07-02 | — | |
| 8-K | — | 2025-06-17 | 2025-06-16 | |
| 8-K | — | 2025-06-16 | 2025-06-13 | |
| SC TO-C | — | 2025-06-16 | — | |
| SC TO-C | — | 2025-06-16 | — | |
| 8-K | — | 2025-05-28 | 2025-05-22 | |
| 10-Q | — | 2025-05-06 | 2025-03-31 | |
| 8-K | — | 2025-05-06 | — |
Showing 1–50 of 213 filings
Key facts
CIK
1356576
CUSIP
868459108
13F (30d)
37 filings
36 filers
Visit website
Investor relations